These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 30081725)

  • 21. Applications of minimal physiologically-based pharmacokinetic models.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):711-23. PubMed ID: 23179857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC.
    Figueroa I; Leipold D; Leong S; Zheng B; Triguero-Carrasco M; Fourie-O'Donohue A; Kozak KR; Xu K; Schutten M; Wang H; Polson AG; Kamath AV
    MAbs; 2018 Jul; 10(5):738-750. PubMed ID: 29757698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
    Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Two-Pore Minimum Physiologically-based Pharmacokinetic Model to Describe the Disposition of Therapeutic Monoclonal IgG Antibody in Humans.
    Hardiansyah D; Ng CM
    Pharm Res; 2018 Feb; 35(3):47. PubMed ID: 29411151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
    Singh AP; Shah DK
    AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey.
    Hardiansyah D; Ng CM
    Eur J Pharm Sci; 2018 Dec; 125():130-141. PubMed ID: 30248389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling.
    Hardiansyah D; Ng CM
    MAbs; 2018 Oct; 10(7):1144-1156. PubMed ID: 29969360
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans.
    Wang H; Rangan VS; Sung MC; Passmore D; Kempe T; Wang X; Thevanayagam L; Pan C; Rao C; Srinivasan M; Zhang Q; Gangwar S; Deshpande S; Cardarelli P; Marathe P; Yang Z
    Biopharm Drug Dispos; 2016 Mar; 37(2):93-106. PubMed ID: 25869904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.
    Avery LB; Wang M; Kavosi MS; Joyce A; Kurz JC; Fan YY; Dowty ME; Zhang M; Zhang Y; Cheng A; Hua F; Jones HM; Neubert H; Polzer RJ; O'Hara DM
    MAbs; 2016; 8(6):1064-78. PubMed ID: 27232760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.
    Cao Y; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.
    Lavezzi SM; Mezzalana E; Zamuner S; De Nicolao G; Ma P; Simeoni M
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):787-802. PubMed ID: 30415351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1.
    Khot A; Tibbitts J; Rock D; Shah DK
    AAPS J; 2017 Nov; 19(6):1715-1734. PubMed ID: 28808917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics.
    Myzithras M; Bigwarfe T; Li H; Waltz E; Ahlberg J; Giragossian C; Roberts S
    MAbs; 2016; 8(8):1606-1611. PubMed ID: 27598372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species.
    Jeong YS; Jusko WJ
    Pharmaceuticals (Basel); 2021 Jun; 14(6):. PubMed ID: 34200427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo efficacy and pharmacological properties of a novel glycopeptide (YV4465) against vancomycin-intermediate Staphylococcus aureus.
    Yarlagadda V; Konai MM; Paramanandham K; Nimita VC; Shome BR; Haldar J
    Int J Antimicrob Agents; 2015 Oct; 46(4):446-50. PubMed ID: 26188396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model.
    Lepak AJ; Andes DR
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4764-9. PubMed ID: 27216072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Across-species meta-analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches.
    Song D; Jusko WJ
    Biopharm Drug Dispos; 2021 May; 42(5):191-203. PubMed ID: 33638217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
    Bulik CC; Okusanya ÓO; Lakota EA; Forrest A; Bhavnani SM; Hoover JL; Andes DR; Ambrose PG
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27872075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics.
    Patidar K; Pillai N; Dhakal S; Avery LB; Mavroudis PD
    J Pharmacokinet Pharmacodyn; 2024 Oct; 51(5):477-492. PubMed ID: 38400996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.